• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials.

作者信息

Müller-Olling Mirco, Vahlensieck Ute, Hilger Anneliese

机构信息

Hematology and Transfusion Medicine, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.

出版信息

Clin Pharmacol Ther. 2022 May;111(5):995-1000. doi: 10.1002/cpt.2281. Epub 2021 Jun 17.

DOI:10.1002/cpt.2281
PMID:34139028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8426852/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c761/8426852/5f972d9b19ce/CPT-111-995-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c761/8426852/5f972d9b19ce/CPT-111-995-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c761/8426852/5f972d9b19ce/CPT-111-995-g001.jpg

相似文献

1
Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials.新冠康复期血浆临床试验中的异质性
Clin Pharmacol Ther. 2022 May;111(5):995-1000. doi: 10.1002/cpt.2281. Epub 2021 Jun 17.
2
What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?2019年冠状病毒病康复期血浆捐献的最佳用途是什么？
Clin Microbiol Infect. 2021 Feb;27(2):163-165. doi: 10.1016/j.cmi.2020.09.036. Epub 2020 Sep 29.
3
Position paper on the use of COVID-19 convalescent plasma: an update.关于使用新冠康复者血浆的立场文件：最新情况
Blood Transfus. 2021 Jul;19(4):277-280. doi: 10.2450/2021.0150-21. Epub 2021 May 21.
4
WHO covid-19 drugs guideline: reconsider using convalescent plasma.世界卫生组织新冠病毒病药物指南：重新考虑使用康复期血浆。
BMJ. 2022 Feb 8;376:o295. doi: 10.1136/bmj.o295.
5
Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.用于治疗新冠病毒肺炎的康复期血浆——解读其中的不一致之处
N Engl J Med. 2022 May 5;386(18):1753-1754. doi: 10.1056/NEJMe2204332.
6
A Public Option for Clinical Trials? Lessons from Convalescent Plasma.临床试验的公共选项？从恢复期血浆中得到的经验教训。
J Law Med Ethics. 2024;52(1):98-100. doi: 10.1017/jme.2024.57. Epub 2024 May 31.
7
Convalescent plasma - this is no time for competition.康复血浆——现在不是竞争的时候。
Transfusion. 2020 Jul;60(7):1644-1646. doi: 10.1111/trf.15922. Epub 2020 Jun 25.
8
Risk-benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19.恢复期血浆疗法在新型冠状病毒肺炎治疗中临床意义的风险效益分析
Postgrad Med J. 2021 Jul;97(1149):467-468. doi: 10.1136/postgradmedj-2020-138056. Epub 2020 Aug 17.
9
The Fast and the Furious: Chasing a Clinical Niche for COVID-19 Convalescent Plasma.《速度与激情：为 COVID-19 恢复期血浆寻找临床定位》。
Ann Intern Med. 2022 Sep;175(9):1332-1334. doi: 10.7326/M22-2329. Epub 2022 Aug 16.
10
Convalescent plasma for COVID-19 considerations.关于新冠病毒病恢复期血浆的考量
Transfus Apher Sci. 2021 Feb;60(1):102927. doi: 10.1016/j.transci.2020.102927. Epub 2020 Aug 27.

引用本文的文献

1
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.下一代治疗方法：针对新冠病毒的免疫疗法和先进疗法。
Heliyon. 2024 Feb 19;10(5):e26423. doi: 10.1016/j.heliyon.2024.e26423. eCollection 2024 Mar 15.
2
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients-An Open-Label Phase II Clinical Trial.新冠康复者恢复期血浆治疗住院患者的疗效与安全性——一项开放标签的II期临床试验
Life (Basel). 2022 Oct 9;12(10):1565. doi: 10.3390/life12101565.
3
A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19.

本文引用的文献

1
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.恢复期血浆治疗与 COVID-19 患者临床结局的关联：系统评价和荟萃分析。
JAMA. 2021 Mar 23;325(12):1185-1195. doi: 10.1001/jama.2021.2747.
2
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.早期高滴度血浆疗法预防老年人重症 COVID-19。
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
3
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
西他列汀与螺内酯联合治疗住院成人 COVID-19 的随机试验。
J Endocr Soc. 2022 Feb 7;6(4):bvac017. doi: 10.1210/jendso/bvac017. eCollection 2022 Apr 1.
4
Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews.新冠康复期血浆疗法的安全性与有效性：系统评价综述
Diagnostics (Basel). 2021 Sep 11;11(9):1663. doi: 10.3390/diagnostics11091663.
新冠康复者血浆或超免疫球蛋白用于新冠肺炎患者：一项实时系统评价
Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600. doi: 10.1002/14651858.CD013600.pub3.
4
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
5
Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?COVID-19 临床试验：我们能否更好地利用短暂的机会窗口？
Clin Pharmacol Ther. 2020 Oct;108(4):730-733. doi: 10.1002/cpt.1891. Epub 2020 Jun 12.
6
A real-time dashboard of clinical trials for COVID-19.新冠肺炎临床试验实时信息平台。
Lancet Digit Health. 2020 Jun;2(6):e286-e287. doi: 10.1016/S2589-7500(20)30086-8. Epub 2020 Apr 24.
7
Deployment of convalescent plasma for the prevention and treatment of COVID-19.恢复期血浆在 COVID-19 预防和治疗中的应用。
J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.
8
SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis.SOFA 评分与随机对照试验中的死亡率终点：系统评价和荟萃回归分析。
Crit Care. 2017 Feb 24;21(1):38. doi: 10.1186/s13054-017-1609-1.
9
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.恢复期血浆和高效免疫球蛋白治疗病毒性病因严重急性呼吸道感染的有效性：系统评价与探索性Meta分析
J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.